Clinical-stage drug development company Nido Biosciences (Nido Bio) raised a total of USD 109 million in seed, Series A, and Series B funding rounds. The Series A round was co-led by 5AM Ventures, Abingworth, and Bessemer Venture Partners, with participation from Osage University Partners and Eli Lilly and Company. Bioluminescence Ventures led the Series B round with participation from additional new investors.
The funds will be used to expedite its lead program, NIDO-361, into clinical trials and build out its pipeline of new programs. The company is also planning to increase its team of drug developers and scientists.
Founded through the 4:59 Initiative at 5AM Ventures, Nido Bio is developing small-molecule precision medicines for debilitating neurological diseases, leveraging advancements in human genetics and disease understanding. Nido Bio’s lead candidate, NIDO-361, is being developed for the treatment of patients with spinal and bulbar muscular atrophy. It also has additional programs addressing neurodegenerative and peripheral inflammatory diseases, utilizing a functional genomics discovery platform based on human cell lines.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.